The Learning Center

Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 1 Component(s) Includes a Live Web Event on 07/31/2024 at 2:00 PM (CDT)

    The ASTCT Pharmacy SIG Rx-cited: Clinical Conundrums Unplugged - Transplant-associated Thrombotic Microangiopathy and Infection Prophylaxis session will air on Wednesday, July 31, 2024 at 2 p.m. CDT/3 p.m. EDT.

    Have you ever found yourself completely stumped on how to approach a clinical case, wishing you could poll pharmacists from other institutions for an immediate answer? Have you ever been curious about other institutions’ transplant or immunotherapy standards, processes, or platforms, but didn’t know where to inquire? Have you posted a question on the SIG Discussion Board in hopes of generating conversation about a unique clinical situation? Have you ever wanted to network with colleagues more often than annually at the Tandem Meetings?

    Then join us for a virtual round table discussion on transplant-associated thrombotic microangiopathy (TA-TMA) and infection prophylaxis! Expect a rapid, informal Q&A session and discussion with your colleagues from around the country with the intent to generate immediate answers and make valuable connections!

    Our second ASTCT Pharmacy SIG’s Rx-Cited: Clinical Conundrums Unplugged will be held on Wednesday, July 31st, at 2 p.m. CDT/3 p.m. EDT. This live session will focus on any clinical and operational questions related to TA-TMA and infection prophylaxis. ASTCT Pharmacy Program Planning Committee will moderate and facilitate conversation from the audience via chat or open dialogue. This is open to all pharmacists practicing in transplantation and cellular therapy. If you have any questions you'd like us to answer at this session, you can submit them here: https://forms.office.com/r/mmWmwHea9T


  • Contains 1 Component(s) Includes a Live Web Event on 06/27/2024 at 3:00 PM (CDT)

    The Best of CAR T at the 2024 Tandem Meetings webinar will air on Thursday, June 27, at 3 p.m. CDT.

    The Best of CAR T at the 2024 Tandem Meetings webinar is the first in a two-part CAR T webinar series. This session will air on Thursday, June 27, at 3 p.m. CDT and will spotlight three talks from the 2024 Tandem Meetings of ASTCT and CIBMTR. This hour-long webinar will have three fifteen-minute talks with the remaining fifteen minutes used for audience Q&A. The session is open and free to all ASTCT members and non-members. 

    Presentations and Speakers:

    Outpatient CAR-T in Action: Models for Staffing and Overcoming Challenges

    David Porter, MD; Director, Center for Cell Therapy and Transplant, University of Pennsylvania

    Role of the Microbiome in Resistance to CAR-T cell Therapies

    Melody Smith, MD; Assistant Professor of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine

    CAR T-cells and Late-Effects, Including Secondary Malignancy

    Aimee Talleur, MD; Assistant Member, Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital


    If you're interested in viewing/purchasing the full session recordings from the 2024 Tandem Meetings of ASTCT and CIBMTR, please click here.


    Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series.

    image
    image
  • Contains 1 Component(s)

    The ASTCT Pharmacy SIG June 2024 Journal Club will air on Wednesday, June 5, 2024 at 2 pm CDT/3 pm EDT.

    The ASTCT Pharmacy SIG June 2024 Journal Club will air on Wednesday, June 5, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the June Journal Club session, Drs. Krajewski and Sowell will present on two articles related to: (a)efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation and (b)gilteritinib as post-transplant maintenance for acute myeloid leukemia. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

    Presenters & Articles

    Kristyn Krajewski, PharmD

    PGY-2 Pharmacy Resident

    Hospital at the University of Pennsylvania

    Article: Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

    Hunter Sowell, PharmD

    PGY-2 Pharmacy Resident

    Vanderbilt University Medical Center

    Article: Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Session Learning Objectives:

    Upon completion of the activity, participants should be able to:

    1. Review impact of FMS-like tyrosine kinase 3 (FLT3) mutation on prognosis and treatment of acute myeloid leukemia (AML).
    2. Evaluate efficacy and safety of gilteritinib as post-transplant maintenance for AML with FLT3-internal tandem duplication (ITD) mutation.
    3. Identify patients who are most likely to benefit from post-transplant gilteritinib maintenance.
    4. Review cytomegalovirus (CMV) infection prophylaxis strategies following hematopoietic stem cell transplant (HSCT).
    5. Analyze the efficacy and safety of extended duration letermovir prophylaxis following HSCT in patients at risk of CMV infection.
    6. Explore the utility of extended duration letermovir for CMV prophylaxis following HSCT.



    ACCREDITED PROVIDER

    This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

    image
    image

          



    image

    In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    CREDIT DESIGNATION

    Pharmacists

    image

    This knowledge-based activity, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

    All other healthcare professionals completing this course will be issued a statement of participation.

    The full CE information for this session can be found here.

  • Contains 1 Component(s)

    The Impact of Subspecialty Palliative Care Consultation in Transplantation and Cellular Therapy aired on Tuesday, May 28, 2024 at 11 am CDT/12 pm EDT.

    This webinar is the second in a series of three presented by the ASTCT Palliative Care SIG. 

    In this session, the speakers will review the evidence base on subspecialty palliative care for improving outcomes in patients undergoing hematopoietic stem cell transplantation and adoptive cellular therapy, and also review the active components of palliative care interventions and how to best integrate them into practice.

    Speakers:

    Dr. Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO
    Associate Professor of Medicine with Tenure
    Duke Cancer Institute

    Deena Levine, MD FAAP FAAHPM
    Interim Division Director
    Medical Director - QOLA Service 
    Division of Quality of Life and Palliative Care
    Department of Oncology
    St. Jude Children’s Research Hospital

    Jason A. Webb, M.D., DFAPA, FAAHPM, FACP (he/him)
    Section Chief, Palliative Care, Division of Hematology & Medical Oncology
    Quality Medical Director, Palliative Care, OHSU Health
    Associate Professor of Medicine & Psychiatry
    OHSU School of Medicine

  • Contains 2 Component(s)

    The Review of FY 2025 IPPS Proposed Rule webinar will air on Wednesday, May 15 from 12 p.m. to 1 p.m. CDT.

    Join ASTCT Director of Government Relations, Alycia Maloney, JD, and the reimbursement and policy advisors to ASTCT from Nimitt Consulting, for the Medicare FY 2025 IPPS Proposed Rule webinar on May 15 at 12 p.m. CDT.

    Maloney and Nimitt will cover multiple CMS proposals for FY 2025, including the following key points:

    • Proposed increases to the MS-DRG base payment rates for stem cell transplant and CAR-T/Other Immunotherapy inpatient Medicare cases, including the following:
      • Allogeneic HSCT (DRG 014) payment rate of $93,891, which is approximately $11,000 more than FY 2024
      • Autologous HSCT (DRGs 016 & 017) payment rate of $43,068, which is a slight decrease from the FY 2024 payment rate of $43,249
        • The recently approved gene therapies for sickle cell disease and transfusion-dependent beta-thalassemia are mapped to these MS-DRGs
      • MS-DRG 018 payment rate of $274,413 – an increase of approximately $16,000 from FY 2024
        • MS-DRG 018 reduced payment rate of approximately $93,000 for clinical trial
    • Proposed Fixed Loss Outlier Threshold amount of $49,237 – an additional loss of approximately $7,000 per case from FY 2024
    • Proposed changes to the New Technology Add-on Payment policies and processes
      • Proposal to pay up to 75% of the determined product cost for gene therapies used to treat sickle cell disease
      • Modification of the third-year anniversary date for a potential third year of NTAP eligibility from April 1 to October 1 (would be effective for FY 2026, not FY 2025) 

    Comments can be submitted to CMS via https://www.regulations.gov and are due by June 10, 2024.

    There will be a Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar to info@astct.org. If you are unable to join, the recording will be made available. 

    Please consider sharing this webinar with your network of physicians, administrators, providers, or any other colleagues that may be interested.

  • Contains 1 Component(s)

    The ASTCT Pharmacy SIG March 2024 Journal Club will air on Wednesday, March 27, 2024 at 2 pm CDT/3 pm EDT

    The ASTCT Pharmacy SIG March 2024 Journal Club will air on Wednesday, March 27, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the March Journal Club session, Drs. Anderson and Boucher will present on two articles related to (a) motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma and (b) recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving CAR T-cell therapy. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

    Presenters & Articles

    Mallori Anderson, PharmD

    PGY-2 Pharmacy Resident

    WVU Medicine

    Article: Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Julie L. Boucher, PharmD, BCPS

    PGY-2 Pharmacy Resident

    Yale New Haven Hospital

    Article: Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

    Session Learning Objectives:

    Upon completion of the activity, participants should be able to:

    1. Describe the effect of bendamustine on chimeric antigen receptor (CAR) efficacy.
    2. Analyze the efficacy outcomes for patients receiving bendamustine before apheresis versus bendamustine naive.
    3. Discuss the safety outcomes related to bendamustine exposure after CAR T-cell therapy, and the impact of prior bendamustine exposure on CAR T-cell expansion.
    4. Review HSC mobilization regimens available for autologous transplantation in multiple myeloma patients.
    5. Describe the mechanism of action of motixafortide and Granulocyte-Colony Stimulating Factor (G-CSF) to mobilize HSCs. 
    6. Evaluate the efficacy and safety of motixafortide and G-CSF compared to plerixafor and G-CSF.




    ACCREDITED PROVIDER

    This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

            image      image


    image

    In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    CREDIT DESIGNATION

    Pharmacists

    image

    This knowledge-based activity, UAN # JA0007204-9999-24-020-L01-P qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

    All other healthcare professionals completing this course will be issued a statement of participation.

    The full CE information for this session can be found here.

  • Contains 2 Component(s)

    Advanced Practice Providers (APPs) play a crucial role in the functioning of transplant and cellular therapy programs of all sizes. Physician Assistant and Nurse Practitioner academic programs provide little training specific to HSCT and cellular therapy. However, this area of health care requires specialized knowledge and skills. Transplant and cellular therapy programs in medical institutions must develop their own educational plans and resources. These can range from very minimal to extensive educational programs depending on the institution. In response, the ASTCT APP SIG (special interest group) identified a need for a standardized document to help better train, onboard, and educate APPs working in transplant and cellular therapy.

    Introduction: Advanced Practice Providers (APPs) play a crucial role in the functioning of transplant and cellular therapy programs of all sizes.  Physician Assistant and Nurse Practitioner academic programs provide little training specific to HSCT and cellular therapy.  However, this area of health care requires specialized knowledge and skills. Transplant and cellular therapy programs in medical institutions must develop their own educational plans and resources. These can range from very minimal to extensive educational programs depending on the institution. In response, the ASTCT APP SIG (special interest group) identified a need for a standardized document to help better train, onboard, and educate APPs working in transplant and cellular therapy. A focus group of experienced APPs in the ASTCT SIG came together to review and update standards while including resources and user-friendly checklists. This document provides a comprehensive framework to support successful onboarding and education of new APPs who will be working with the cellular therapy patient population. It provides guidance for both the orientee and the mentor.  Resources included in this document are current (within 5 years if available) and highlight established consensus guidelines, evidence-based practice & current research. Currently, the goal is to review this document every 3-5 years to maintain an up-to-date onboarding and education program moving forward. 

    Using This Document: This document aims to serve as a template and supplement to institutional onboarding programs. Each APP will have unique needs and baseline knowledge. As a result, this document can serve as a guide but may require changes to meet a specific need. As a new APP makes its way through this onboarding list, it is important that managers, team leads, and preceptors schedule intermittent meetings to check in and assess progress. Areas with a *** are competencies that FACT recommends.  While we suggest weeks for the different objectives, preceptors and trainees will likely be working on multiple areas of this document at the same time and do not need to work in a linear fashion. The assessment section is meant to help track progress through the document as well as progress through orientation.  Assessments may be based on activities, objectives, or resources.  The larger assessment sections have room to leave notes for both orientee and preceptor.

    Acknowledgements: a special thank you to those who made this document a reality.

    Maritza Alencar, DNP, MBA, APRN-BC, BMTCN

    Misty Evans, DNP, APRN, CPNP-AC, BMTCN

    Mary Guay, PA-C

    Chelsea Honstain, MS, FNP-C, BMTCN

    Rita M. Jakubowski DNP, RN, ANP-BC, OCN, BMTCN

    Sarah Jimenez DNP, AGACNP, AOCNP

    Samantha Newman, MSN, PNP-AC, BMTCN

    Zandra Rivera,DNP, ANP-BC, BMTCN

    Liza Rodriguez, DNP, MSN, FNP-C, AOCNP

    Nancy Shreve, RN, MS, FNP, BMTCN

    Jannelle Vicens, DNP, MSN FNP-BC, BSN

    Elizabeth Zerante MS, AGACNP-BC


  • Contains 1 Component(s)

    The ASTCT Pharmacy SIG November 2023 Journal Club will air on Wednesday, November 29, 2023 at 2 pm CST/3 pm EST.

    The ASTCT Pharmacy SIG November 2023 Journal Club will air on Wednesday, November 29, 2023 at 2 pm CST/3 pm EST. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the November Journal Club session, Drs. Patel and Gash will present on two articles related to (a) ciltacabtagene autoleucel or standard of care treatment in lenalidomide-refractory multiple myeloma and (b) post-transplant cyclophosphamide, abatacept, and a short course of tacrolimus (CAST) after peripheral blood haploidentical HSCT. 

    This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

    Presenters & Articles

    Shikha P. Patel, PharmD, BCPS

    PGY-2 Pharmacy Resident

    Mayo Clinic

    Article: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

     

    Kyle Gash, PharmD

    PGY-2 Pharmacy Resident

    Moffitt Cancer Center

    Article: PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

    Session Learning Objectives:

    Upon completion of the activity, participants should be able to:

    1. Review the role of CAR T-cell therapy in relapsed/refractory multiple myeloma
    2. Describe the mechanism of action of ciltacabtagene autoleucel
    3. Evaluate the efficacy and safety of ciltacabtagene autoleucel compared to standard regimens in the management of relapsed/refractory multiple myeloma
    4. Review graft-versus-host disease (GVHD) prophylaxis regimens following haploidentical hematopoietic stem cell transplantation (HCT)
    5. Analyze the safety and efficacy of post-transplant cyclophosphamide (PTCy), abatacept, and a short course of tacrolimus (CAST) for GVHD prevention
    6. Discuss the utility of the CAST regimen for GVHD prevention after haploidentical HCT



    ACCREDITED PROVIDER

    This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

            image      image


    image

    In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    CREDIT DESIGNATION

    Pharmacists

    image

    This knowledge-based activity, UAN JA0007204-9999-23-041-L01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

    All other healthcare professionals completing this course will be issued a statement of participation.

    The full CE information for this session can be found here.

  • Contains 10 Product(s)

    These are all the recordings and slides of the ten sessions from the live event the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. Purchase this package to get access to all ten sessions at a discounted rate!

    These are the recordings and slides of the four sessions from the live event the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. This live event took place on October 2 and 3, 2023. The two-day, hybrid workshop offered providers, payers, government agencies, and industry involved in the field of cell and gene therapy increased educational and advocacy opportunities. This workshop featured educational sessions bridging the gap among stakeholders, and identify ongoing needs and opportunities in the field for advocacy, measurement of value and impact, and sustainability.

    Purchase this package to get access to all ten sessions at a discounted rate! Individuals who registered to attend this event live are eligible to receive access to these recordings free of charge. Please email info@astct.org to receive your discount.

  • Contains 4 Component(s)

    This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.

    This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.

    Topics include:

    • CAR-T Barriers to Care
    • Point of Care Manufacture of CAR T cells
    • Point of Care Manufacturing: Enabling affordable and accessible advanced medicines

    Session Chair:

    • Boro Dropulić, PhD, MBA; Caring Cross

    Speakers: 

    • Armin Ghobadi, MD; Washington University School of Medicine
    • Marcos de Lima, MD; The Ohio State University Comprehensive Cancer Center
    • Boro Dropulić, PhD, MBA; Caring Cross